Trial
NCT02698189
A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Hematologic Malignancies (MK-8628-005)
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Merck Sharp & Dohme LLC
Collaborators
—
Condition
AML Including AML de Novo and AML Secondary to MDS
Intervention
Birabresib Dose 20 mg
Why stopped
This study was terminated due to limited efficacy and not due to safety reasons
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-09-13